[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-406453-105":59,"doc-detail-406453-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unmasking-the-high-risk-phenotype-in-autoimmune-gastritis-a-pathologists-roadmap-for-the-clinician","Unmasking the high-risk phenotype in autoimmune gastritis - A pathologist’s roadmap for the clinician","","Li et al’s recent work on the risk factors for autoimmune gastritis provides clinical context for the vast majority of gastric neuroendocrine tumors (G-NETs). However, a deeper understanding of the underlying pathology is needed for precise clinical management. This letter details the predictable stepwise progression of type 1 G-NETs, from autoimmune-driven corporal atrophy and hypergastrinemia, through defined microscopic precursor stages. It specifies diagnostic thresholds separating precursors from overt neoplasia, including a 0.5 mm size rule and submucosal invasion, and proposes a prognostic biopsy protocol using Ki-67 grading. This pathology-centric strategy enables objective, earlier risk-guided surveillance rather than waiting for visible tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unmasking-the-high-risk-phenotype-in-autoimmune-gastritis-a-pathologists-roadmap-for-the-clinician/406453/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unmasking-the-high-risk-phenotype-in-autoimmune-gastritis-a-pathologists-roadmap-for-the-clinician/406453.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What key diagnostic thresholds are used to separate precursor lesions from overt neoplasia in autoimmune gastritis-related G-NETs?","Question",{"text":112,"@type":113},"The letter highlights a 0.5 mm size rule and the presence of submucosal invasion as decisive thresholds that distinguish precursor lesions from overt neoplasia.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What progression does the letter describe for type 1 gastric neuroendocrine tumors in autoimmune gastritis?",{"text":117,"@type":113},"It outlines a predictable stepwise sequence: autoimmune-driven corporal atrophy and hypergastrinemia followed by a microscopic path that includes enterochromaffin-like cell precursor lesions such as linear hyperplasia, micronodular hyperplasia, and dysplasia.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the proposed “prognostic biopsy protocol” change clinical surveillance?",{"text":121,"@type":113},"It asks pathologists to report specific precursor lesion stages and to use Ki-67 to grade G-NETs, enabling quantitative risk assessment so clinicians can intensify surveillance based on objective microscopic milestones rather than macroscopic tumor appearance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},406453,1791384880,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2025 December 28; 31(48): 115244  \nDOI: 10.3748/wjg.v31.i48.115244 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \nLETTER TO THE EDITOR  \nUnmasking the high-risk phenotype in autoimmune gastritis: A pathologist’s roadmap for the clinician  \nCheng-Long Wang, Min Zeng, Yan Luo  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade B, Grade B  \nNovelty: Grade B, Grade D  \nCreativity or Innovation: Grade B, Grade C  \nScientific Significance: Grade B, Grade B  \nP-Reviewer: Cerwenka H, MD, Professor, Austria; Shukla A, MD, Assistant Professor, India  \nReceived: October 15, 2025  \nRevised: October 28, 2025  \nAccepted: November 12, 2025  \nPublished online: December 28, 2025  \nProcessing time: 76 Days and 0.5 Hours  \nCheng-Long Wang, Min Zeng, Department of Pathology, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400021, China  \nYan Luo, Department of Stomatology, The People’s Hospital of Dadukou District, Chongqing 400084, China  \nCo-corresponding authors: Min Zeng and Yan Luo.  \nCorresponding author: Yan Luo, MD, Doctor, Department of Stomatology, The People’s Hospital of Dadukou District, No. 102 Cuibai Road, Dadukou District, Chongqing 400084, [China.](China. luokate88@gmail.com)[ luokate88@gmail.com](China. luokate88@gmail.com)  \nAbstract  \nLi et al’s recent work on the risk factors for autoimmune gastritis provides clinical context for the vast majority of gastric neuroendocrine tumors (G-NETs) . However, a deeper understanding of the underlying pathology is needed for precise clinical management. Our letter details the predictable stepwise progression of type 1 G-NETs from autoimmune-driven corporal atrophy and hypergastrinemiato a clear microscopic sequence of enterochromaffin-like cell precursor lesions, including linear hyperplasia, micronodular hyperplasia, and dysplasia. We highlight the definitive diagnostic thresholds that separate these precursors from overt neoplasia: The 0.5 mm size rule and the presence of submucosal invasion. We advocate for a “prognostic biopsy protocol” in which pathologists actively report these precursor lesions and use Ki-67 to grade G-NETs, providing a quantitative risk assessment. This pathology-centric approach transforms surveillance, allowing clinicians to act on objective microscopic milestones rather than waiting for macroscopically visible tumors.  \nKey Words: Pathology; Autoimmune gastritis; Gastric neuroendocrine tumors; Precursor lesions; Dysplasia  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \n WJG  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 28, 2025  Volume 31  Issue 48   \nWang CL et al. Pathology-guided risk in AIG  \nCore Tip: Clinical risk models identify patients with autoimmune gastritis who may develop neuroendocrine tumors, but pathology guides what to do next. We advocate for a “prognostic biopsy protocol” where pathologists report the specific stage of microscopic pre-cancerous lesions. Finding high-risk changes, especially dysplasia, serves as a clear trigger to intensify surveillance. This approach allows clinicians to manage risk proactively based on a patient’s real-time biology, rather than waiting for a visible tumor to develop.  \nCitation: Wang CL, Zeng M, Luo Y. Unmasking the high-risk phenotype in autoimmune gastritis: A pathologist’s roadmap for the clinician. World J Gastroenterol 2025; 31(48): 115244  \nURL: [https://www.wjgnet.com/1007-9327/full/v31/i48/115244.htm](https://www.wjgnet.com/1007-9327/full/v31/i48/115244.htm)  \nDOI: [https://dx.doi.org/10.3748/wjg.v31.i48.115244](https://dx.doi.org/10.3748/wjg.v31.i48.115244)  \nTO THE EDITOR  \nWe ","cbCaicHaCf59wINR","https://ap.wps.com/l/cbCaicHaCf59wINR","pdf",3488917,"English","# LETTER TO THE EDITOR\n## Unmasking the high-risk phenotype in autoimmune gastritis\n# TO THE EDITOR\n# Core Tip\n# BEYOND ENDOSCOPY: DEFINING NEOPLASTIC RISK THROUGH PATHOLOGICAL CORRELATION","[{\"question\":\"What key diagnostic thresholds are used to separate precursor lesions from overt neoplasia in autoimmune gastritis-related G-NETs?\",\"answer\":\"The letter highlights a 0.5 mm size rule and the presence of submucosal invasion as decisive thresholds that distinguish precursor lesions from overt neoplasia.\"},{\"question\":\"What progression does the letter describe for type 1 gastric neuroendocrine tumors in autoimmune gastritis?\",\"answer\":\"It outlines a predictable stepwise sequence: autoimmune-driven corporal atrophy and hypergastrinemia followed by a microscopic path that includes enterochromaffin-like cell precursor lesions such as linear hyperplasia, micronodular hyperplasia, and dysplasia.\"},{\"question\":\"How does the proposed “prognostic biopsy protocol” change clinical surveillance?\",\"answer\":\"It asks pathologists to report specific precursor lesion stages and to use Ki-67 to grade G-NETs, enabling quantitative risk assessment so clinicians can intensify surveillance based on objective microscopic milestones rather than macroscopic tumor appearance.\"}]","Unmasking the high-risk phenotype in autoimmune gastritis - A pathologist’s roadmap for the clinician | PDF",1790565764,15]